Green tea and one of its constituents, epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Hintzpeter, Jan ^a   Stapelfeld, Claudia ^a   Loerz, Christine ^a   Martin, Hans Joerg ^a   Maser, Edmund ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CATECHIN; CORTISONE; EPICATECHIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GALLOCATECHIN; GREEN TEA EXTRACT; HYDROGEN PEROXIDE;

ARTICLE; BINDING COMPETITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; IC 50; LIVER MICROSOME; MOLECULAR DOCKING; OXIDATION; PLANT LEAF; WESTERN BLOTTING;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; CATECHIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; KINETICS; MICROSOMES, LIVER; PLANT EXTRACTS; TEA;

EID: 84896797237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084468     Document Type: Article

References (44)

1. Macfarlane (2004) The Empire of Tea. The Overlook Press.
2. Sang S, Lambert JD, Ho C-T, Yang CS (2011) The chemistry and biotransformation of tea constituents. Pharmacol Res Off J Ital Pharmacol Soc 64: 87-99. doi:10.1016/j.phrs.2011.02.007.
3. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K (2000) Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors Oxf Engl 13: 49-54. (Pubitemid 32107344)
4. Sato Y, Nakatsuka H, Watanabe T, Hisamichi S, Shimizu H, et al. (1989) Possible contribution of green tea drinking habits to the prevention of stroke. Tohoku J Exp Med 157: 337-343. (Pubitemid 19196202)
5. Setiawan VW, Zhang ZF, Yu GP, Lu QY, Li YL, et al. (2001) Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer J Int Cancer 92: 600-604. (Pubitemid 32319436)
6. Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, et al. (2001) A new function of green tea: prevention of lifestyle-related diseases. Ann N Y Acad Sci 928: 274-280. (Pubitemid 32386088)
7. Grove KA, Lambert JD (2010) Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr 140: 446-453. doi:10.3945/jn.109.115972.
8. Cabrera C, Artacho R, Giménez R (2006) Beneficial effects of green tea-a review. J Am Coll Nutr 25: 79-99. (Pubitemid 46939847)
9. Chacko SM, Thambi PT, Kuttan R, Nishigaki I (2010) Beneficial effects of green tea: a literature review. Chin Med 5: 13. doi:10.1186/1749-8546-5-13.
10. Sae-tan S, Grove KA, Lambert JD (2011) Weight control and prevention of metabolic syndrome by green tea. Pharmacol Res Off J Ital Pharmacol Soc 64: 146-154. doi:10.1016/j.phrs.2010.12.013.
11. Ihm S-H, Jang S-W, Kim O-R, Chang K, Oak M-H, et al. (2012) Decaffeinated green tea extract improves hypertension and insulin resistance in a rat model of metabolic syndrome. Atherosclerosis 224: 377-383. doi:10.1016/j. atherosclerosis. 2012.07.006.
12. Thielecke F, Boschmann M (2009) The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry 70: 11-24. doi:10.1016/j.phytochem.2008.11.011.
13. Brown AL, Lane J, Coverly J, Stocks J, Jackson S, et al. (2009) Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3- gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr 101: 886-894. doi:10.1017/S0007114508047727.
14. Maeda-Yamamoto M (2013) Human clinical studies of tea polyphenols in allergy or life style-related diseases. Curr Pharm Des.
15. Ikeda I (2008) Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac J Clin Nutr 17 Suppl 1: 273-274.
16. Suzuki Y, Miyoshi N, Isemura M (2012) Health-promoting effects of green tea. Proc Jpn Acad Ser B Phys Biol Sci 88: 88-101.
17. Bhagwat S (2011) USDA Database for the Flavonoid Contents of Selected Foods.
18. Harbowy ME, Balentine DA, Davies AP, Cai Y (1997) Tea Chemistry. Crit Rev Plant Sci 16: 415-480. doi:10.1080/07352689709701956.
19. Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37: 693-704. doi:10.1080/10408399709527797. (Pubitemid 127349613)
20. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S (2009) Antidiabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 102: 1703-1708. doi:10.1017/S0007114509992054.
21. Shen Y, Hu Y, Chen B, Yao S (2010) Screening of enzyme inhibitors from traditional Chinese medicine. Comb Chem High Throughput Screen 13: 885-899.
22. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, et al. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170. doi:10.1126/science.1066285. (Pubitemid 33150673)
23. Blum A, Maser E (2003) Enzymology and molecular biology of glucocorticoid metabolism in humans. Prog Nucleic Acid Res Mol Biol 75: 173-216. (Pubitemid 137639558)
24. Maser E, Völker B, Friebertshäuser J (2002) 11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry (Mosc) 41: 2459-2465. (Pubitemid 34160910)
25. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, et al. (2004) 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-866. doi:10.1210/er.2003-0031. (Pubitemid 39366049)
26. White PC, Mune T, Agarwal AK (1997) 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135-156. (Pubitemid 27076458)
27. Wamil M, Seckl JR (2007) Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 12: 504-520. doi:10.1016/j.drudis.2007.06.001. (Pubitemid 47031664)
28. Staab CA, Maser E (2010) 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol 119: 56-72. doi:10.1016/j.jsbmb.2009.12.013.
29. Morton NM, Seckl JR (2008) 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 36: 146-164. doi:10.1159/0000115363.
30. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, et al. (2005) Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54: 1023-1031. (Pubitemid 40446315)
31. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, et al. (2004) Metabolic syndrome without obesity: Hepatic overexpression of 11betahydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101: 7088-7093. doi:10.1073/pnas.0305524101. (Pubitemid 38596447)
32. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, et al. (1997) 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 94: 14924-14929. (Pubitemid 28041476)
33. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, et al. (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276: 41293-41300. doi:10.1074/jbc.M103676200.
34. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, et al. (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931-938. (Pubitemid 38436604)
35. Blum A, Martin HJ, Maser E (2000) Human 11beta-hydroxysteroid dehydrogenase 1/carbonyl reductase: recombinant expression in the yeast Pichia pastoris and Escherichia coli. Toxicology 144: 113-120. (Pubitemid 30201627)
36. Blum A, Loerz C, Martin H-J, Staab-Weijnitz CA, Maser E (2012) Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11bhydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 128: 51-55. doi:10.1016/j.jsbmb.2011.09.003.
37. Halliwell B (2008) Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys 476: 107-112. doi:10.1016/j.abb.2008.01.028.
38. Long LH, Clement MV, Halliwell B (2000) Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate, (+)-catechin, and quercetin to commonly used cell culture media. Biochem Biophys Res Commun 273: 50-53. doi:10.1006/bbrc.2000. 2895. (Pubitemid 30426861)
39. Dringen R, Kussmaul L, Hamprecht B (1998) Detoxification of exogenous hydrogen peroxide and organic hydroperoxides by cultured astroglial cells assessed by microtiter plate assay. Brain Res Brain Res Protoc 2: 223-228. (Pubitemid 28277484)
40. Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, et al. (2012) Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 61: 1357-1364. doi:10.2337/db11-1345.
41. Ge R, Huang Y, Liang G, Li X (2010) 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr Med Chem 17: 412-422.
42. Szelényi P, Révész K, Konta L, Tüttõ A, Mandl J, et al. (2013) Inhibition of microsomal cortisol production by (-)-epigallocatechin-3-gallate through a redox shift in the endoplasmic reticulum-A potential new target for treating obesity-related diseases. BioFactors Oxf Engl. doi:10.1002/biof.1095.
43. Grosdidier A, Zoete V, Michielin O (2011) Swiss Dock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39: W270-277. doi:10.1093/nar/gkr366.
44. Weng Z, Greenhaw J, Salminen WF, Shi Q (2012) Mechanisms for epigallocatechin gallate induced inhibition of drug metabolizing enzymes in rat liver microsomes. Toxicol Lett 214: 328-338. doi:10.1016/j.toxlet. 2012.09.011.